Affimed NV (AFMD)
5.96
+0.09
(+1.53%)
USD |
NASDAQ |
Jun 24, 16:00
5.90
-0.06
(-1.01%)
After-Hours: 20:00
Affimed Research and Development Expense (Annual): 102.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 102.80M |
| December 31, 2022 | 104.21M |
| December 31, 2021 | 96.42M |
| December 31, 2020 | 57.09M |
| December 31, 2019 | 49.02M |
| December 31, 2018 | 41.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 24.34M |
| December 31, 2016 | 33.40M |
| December 31, 2015 | 24.42M |
| December 31, 2014 | 12.76M |
| December 31, 2013 | 19.06M |
| December 31, 2012 | 11.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
49.02M
Minimum
2019
104.21M
Maximum
2022
81.91M
Average
96.42M
Median
2021
Research and Development Expense (Annual) Benchmarks
| CureVac NV | 125.28M |
| InflaRx NV | 44.41M |
| MorphoSys AG | 307.04M |
| BioNTech SE | 1.930B |
| Immatics NV | 128.47M |